"A Pretty Good Understanding" of SARS


As an epidemic of a mystery virus sweeps from China and Hong Kong to the rest 
of the world (see BW Online, 4/4/03, "The Day Hong Kong Shut Its Doors") 
treatment remains elusive. About 80% of those who get the illness, dubbed 
severe acute respiratory syndrome (SARS), seem to recover fully after a few 
weeks. But the rest get very sick. The worst symptom: Their lungs fill up 
with fluid, making it difficult to breathe -- and to get enough oxygen into 
their bodies. Respirators can help, but not always. Four percent of patients 
die. 

That has touched off a frantic search to find a medicine or vaccine that can 
help. Dr. Donald E. Low of Mount Sinai Hospital in Toronto is at the 
forefront of that search, and he's at the center of the outbreak in Canada -- 
which began when an elderly woman brought the disease back from Hong Kong. 
Since then, he has treated dozens of patients. In fact, he has been exposed 
to the disease himself and is now under isolation in case he's infected. 

Low says "we're now able to speculate about exactly what happened -- and we 
have a pretty good understanding of what's going on." The evidence suggests 
that somewhere in Southern China, a virus that normally infects animals 
jumped to a person -- "probably a farmer or someone in close contact with 
animals," says Low. 

ONE EXCEPTION. The virus, he suggests, doesn't do all that well in people. 
That's why my most people manage to fight off the infection. But some people 
develop a very severe pneumonia. Why? 

In Canada, Low and his colleagues have found two things that predict how hard 
the disease will strike. One is that virtually all of those who died were 
either elderly or had other, chronic diseases, or both. Those who are young 
and healthy appear to be far more capable of fighting off the virus. With one 
exception: Those who are exposed to a huge dose of the virus can die 
regardless of how strong and healthy there are. 

Low points out that the elderly woman who brought the disease to Toronto had 
a 43-year old son, who helped care for her when she fell ill. Over the course 
of her illness, doctors speculate, the son got a huge dose of virus. "I bet 
he got a massive exposure," says Low. He soon became ill himself and died on 
Mar. 13, eight days after his mother passed away. 

TWO APPROACHES. Based on study of the disease so far, Low believes that his 
team has made progress in treating it. Scientists now think the fluid in the 
lungs is caused by a biochemical mechanism that involves chemical messengers 
in the immune system called cytokines. Somehow -- the exact mechanisms aren't 
yet known -- the virus triggers cells in the immune system to make far too 
many cytokines. The cytokines, in turn, cause the capillaries (small blood 
vessels) in lung tissue to leak fluid into the lungs. 

Doctors thought there might be two ways to tackle this deadly chain of 
events. One is to try to knock the virus back directly with an antiviral drug 
like ribavarin. But Low says he has treated 20 patients with ribavarin "and 
I've not been impressed," he says. "It's not a great drug -- at least in the 
test tube" against this virus. 

The other approach is to try to dampen the immune response just enough to 
keep the amount of cytokines (and thus the fluid in the lungs) from getting 
dangerously high. The drugs of choice: steroids. But steroids can be a 
double-edged sword. Even as they dampen the cytokine response, they may also 
dampen the immune system's ability to make antibodies against the virus. 
These antibodies are crucial to fighting off the microbe. And "steroids may 
allow more viral reproduction," Low explains. 

A BETTER WAY? So the approach Low and others are now using combines both 
steroids and ribavarin. The hope is that the ribavarin, even though it's not 
very potent against the virus, might slow it down just enough to counteract 
the steroids' bad effects on the immune system. That way, the steroids' good 
effects -- reducing fluid in the lung -- can help patients live long enough 
for their antibodies to kick in, finally conquering the virus. 

"In our more recent patients, we started ribavarin and steroids at the same 
time -- and they've done very well," says Low. But something else should work 
a lot better, he says. Ample evidence shows that the body's immune system can 
make antibodies against the virus. So what if doctors took those antibodies 
and gave them to sick people? 

The idea "definitely warrants further investigation," says Low. The same 
approach has worked well in other dangerous infections, he says. "The 
challenge is to find patients who have recovered and to harvest antibodies 
from them," he says. But if that can be done, "it could be a very attractive 
treatment." 

"MY BIG CONCERN." Low believes that Canada and other countries with strong 
public-health systems will be able to control their outbreaks. But maybe not 
so in the rest of the world: "My big concern is that if it goes into 
countries with no resources, no expertise, [and] no infrastructure, it will 
become a pandemic," he says. That means it would keep spreading from person 
to person for years to come -- and periodically come back to haunt countries 
that managed to stamp it out this time around. 

If that happens, Low hopes, at least by then doctors will be better equipped 
to handle it. "If we can control the outbreak in this country now, it will 
give us the lead time to get vaccines and better treatments, so we'll be more 
prepared when it comes back," he says. In the meantime, the research goes on. 




------------------------------------------------------------------------ 


--
The silver-list is a moderated forum for discussion of colloidal silver.

Instructions for unsubscribing may be found at: http://silverlist.org

To post, address your message to: [email protected]

Silver-list archive: http://escribe.com/health/thesilverlist/index.html

List maintainer: Mike Devour <[email protected]>